MGMary R. Guest

Mary R. Guest

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mary R. Guest has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Structures of dynamic interactors at native proteasomes by PhIX-MS and cryo-electron microscopy

    by Kitaik Lee, Hitendra Negi, Xiang Chen, Katerina Atallah-Yunes, Sophia Truslow, Rithik E. Castelino, Mary R. Guest, Anthony M. Ciancone, Xiuxiu Lu, Sergey G. Tarasov, et al.


  • Open Access

    Structures of dynamic interactors at native proteasomes by PhIX-MS and cryoelectron microscopy

    by Kitaik Lee, Hitendra Negi, Xiang Chen, Katerina Atallah-Yunes, Sunny Truslow, Rithik E. Castelino, Mary R. Guest, Anthony M. Ciancone, Sergey G. Tarasov, Raj Chari, et al.

    Summary: Proteasome function depends on a network of transient interactions that remain structurally and functionally unresolved. We developed PhIX-MS (Photo-induced In situ Crosslinking-Mass Spectrometry), a structural proteomics workflow that stabilizes transient interactions in cells by UV-activated crosslinking to capture topological information. Applying PhIX-MS with cryo-electron microscopy (cryo-EM), we mapped redox sensor TXNL1 at the proteasome regulatory particle (RP), placing its PITH domain above deubiquitinase RPN11 and resolving its dynamic thioredoxin domain near RPN2/PSMD1 and RPN13/ADRM1, ideally located to reduce substrates prior to proteolysis. We also resolved chaperone PSMD5 bound to RP without the proteolytic core particle (CP) where its C-terminus inserts into the ATPase pore blocking CP binding. PhIX-MS and AlphaFold modeling tether ubiquitin ligase UBE3C/Hul5 along the RP placing its catalytic site above the RPN11 active site, enabling their coupled activities. Our integrative approach enables the localization of native, low-affinity protein interactions and is broadly applicable to dynamic macromolecular assemblies.


  • Open Access

    Uncovering receptor-ligand interactions using a high-avidity CRISPR activation screening platform

    by Liping Yang, Timothy P. Sheets, Yang Feng, Guojun Yu, Pradip Bajgain, Kuo-Sheng Hsu, Daeho So, Steven Seaman, Jaewon Lee, Ling Lin, et al.

    The majority of clinically approved drugs target proteins that are secreted or cell surface bound. However, further advances in this area have been hindered by the challenging nature of receptor deorphanization, as there are still many secreted and cell-bound proteins with unknown binding partners. Here, we developed an advanced screening platform that combines CRISPR-CAS9 guide–mediated gene activation (CRISPRa) and high-avidity bead-based selection. The CRISPRa platform incorporates serial enrichment and flow cytometry–based monitoring, resulting in substantially improved screening sensitivity for well-known yet weak interactions of the checkpoint inhibitor family. Our approach has successfully revealed that siglec-4 exerts regulatory control over T cell activation through a low affinity trans-interaction with the costimulatory receptor 4-1BB. Our highly efficient screening platform holds great promise for identifying extracellular interactions of uncharacterized receptor-ligand partners, which is essential to develop next-generation therapeutics, including additional immune checkpoint inhibitors.